Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.

Hampsch RA, Shee K, Bates D, Lewis LD, Désiré L, Leblond B, Demidenko E, Stefan K, Huang YH, Miller TW.

Oncotarget. 2017 Mar 28;8(13):21806-21817. doi: 10.18632/oncotarget.15586.

2.

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.

Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, Van Etten RA.

Haematologica. 2017 Mar;102(3):519-528. doi: 10.3324/haematol.2016.152710. Epub 2016 Dec 7.

3.

The Synthetic β-Nitrostyrene Derivative CYT-Rx20 Inhibits Esophageal Tumor Growth and Metastasis via PI3K/AKT and STAT3 Pathways.

Chiu WC, Lee YC, Su YH, Wang YY, Tsai CH, Hou YA, Wang CH, Huang YF, Huang CJ, Chou SH, Hsieh PW, Yuan SF.

PLoS One. 2016 Nov 22;11(11):e0166453. doi: 10.1371/journal.pone.0166453. eCollection 2016.

4.

c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's Disease.

Lindholm D, Pham DD, Cascone A, Eriksson O, Wennerberg K, Saarma M.

Front Aging Neurosci. 2016 Oct 26;8:254. eCollection 2016. Review.

5.

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth.

Rovithi M, de Haas RR, Honeywell RJ, Poel D, Peters GJ, Griffioen AW, Verheul HM.

J Exp Clin Cancer Res. 2016 Sep 7;35(1):138. doi: 10.1186/s13046-016-0411-2.

6.

Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.

Jin Y, Yao Y, Chen L, Zhu X, Jin B, Shen Y, Li J, Du X, Lu Y, Jiang S, Pan J.

Theranostics. 2016 Aug 12;6(11):1947-62. doi: 10.7150/thno.16139. eCollection 2016.

7.

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.

Abraham SA, Hopcroft LE, Carrick E, Drotar ME, Dunn K, Williamson AJ, Korfi K, Baquero P, Park LE, Scott MT, Pellicano F, Pierce A, Copland M, Nourse C, Grimmond SM, Vetrie D, Whetton AD, Holyoake TL.

Nature. 2016 Jun 16;534(7607):341-6. doi: 10.1038/nature18288. Epub 2016 Jun 8.

8.

Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.

Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, Jenkins RL, Rieger-Christ KM, Sullivan TB, Hezel AF, Liss AS, Mizukami Y, Goyal L, Ferrone CR, Zhu AX, Joung JK, Shokat KM, Benes CH, Bardeesy N.

Cancer Discov. 2016 Jul;6(7):727-39. doi: 10.1158/2159-8290.CD-15-1442. Epub 2016 May 26.

9.

Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors.

Toska E, Baselga J.

Clin Cancer Res. 2016 May 1;22(9):2099-101. doi: 10.1158/1078-0432.CCR-16-0038. Epub 2016 Mar 8.

10.

A dose-schedule finding design for phase I-II clinical trials.

Guo B, Li Y, Yuan Y.

J R Stat Soc Ser C Appl Stat. 2016 Feb;65(2):259-272. Epub 2016 Aug 10.

11.

Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.

Testoni E, Stephenson NL, Torres-Ayuso P, Marusiak AA, Trotter EW, Hudson A, Hodgkinson CL, Morrow CJ, Dive C, Brognard J.

EMBO Mol Med. 2016 Feb 1;8(2):105-16. doi: 10.15252/emmm.201505456.

12.

Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.

Yang W, Hosford SR, Dillon LM, Shee K, Liu SC, Bean JR, Salphati L, Pang J, Zhang X, Nannini MA, Demidenko E, Bates D, Lewis LD, Marotti JD, Eastman AR, Miller TW.

Clin Cancer Res. 2016 May 1;22(9):2250-60. doi: 10.1158/1078-0432.CCR-15-2276. Epub 2016 Jan 5.

13.

Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells.

Amin AD, Rajan SS, Groysman MJ, Pongtornpipat P, Schatz JH.

Biomark Cancer. 2015 Dec 15;7(Suppl 2):25-32. doi: 10.4137/BIC.S29326. eCollection 2015. Review.

14.

Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.

Lue HW, Cole B, Rao SA, Podolak J, Van Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, Heiser LM, Tyner JW, Thomas GV.

Oncotarget. 2015 Dec 29;6(42):44675-87. doi: 10.18632/oncotarget.5971.

15.

Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer.

Schöttle J, Chatterjee S, Volz C, Siobal M, Florin A, Rokitta D, Hinze Y, Dietlein F, Plenker D, König K, Albus K, Heuckmann JM, Rauh D, Franz T, Neumaier B, Fuhr U, Heukamp LC, Ullrich RT.

Oncotarget. 2015 Nov 17;6(36):38458-68. doi: 10.18632/oncotarget.6276.

16.

The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.

Ko TK, Chin HS, Chuah CT, Huang JW, Ng KP, Khaw SL, Huang DC, Ong ST.

Oncotarget. 2016 Jan 19;7(3):2721-33. doi: 10.18632/oncotarget.5436.

17.
18.

Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet.

McArthur GA.

Front Oncol. 2015 Jul 17;5:161. doi: 10.3389/fonc.2015.00161. eCollection 2015. Review. No abstract available.

19.

Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.

Pagliarini R, Shao W, Sellers WR.

EMBO Rep. 2015 Mar;16(3):280-96. doi: 10.15252/embr.201439949. Epub 2015 Feb 13. Review.

20.

Supplemental Content

Support Center